This document discusses the dispute surrounding the proxy contest between Amylin Pharmaceuticals, Inc. and its stockholders, Icahn Capital LP and affiliated funds and Eastbourne Capital Management, L.L.C., and provides a summary of key litigated issues and practical implications indicated by the litigation.